{
    "name": "enoxaparin",
    "comment": "Rx",
    "other_names": [
        "Lovenox"
    ],
    "classes": [
        "Anticoagulants",
        "Cardiovascular",
        "Anticoagulants",
        "Hematologic",
        "Low Molecular Weight Heparin"
    ],
    "source": "https://reference.medscape.com/drug/lovenox-enoxaparin-342174",
    "pregnancy": {
        "common": [
            "Human data from a retrospective cohort study, suggest that enoxaparin does not increase risk of major developmental abnormalities",
            "Pregnancy alone confers increased risk for thromboembolism that is higher for women with thromboembolic disease and certain high risk pregnancy conditions; while not adequately studied, pregnant women with mechanical prosthetic heart valves may be at even higher risk for thrombosis; pregnant women with thromboembolic disease, including those with mechanical prosthetic heart valves and those with inherited or acquired thrombophilias, have an increased risk of other maternal complications and fetal loss regardless of type of anticoagulant used",
            "All patients receiving anticoagulants, including pregnant women, are at risk for bleeding; pregnant women receiving drug should be carefully monitored for evidence of bleeding or excessive anticoagulation",
            "Hemorrhage can occur at any site and may lead to death of mother and/or fetus; pregnant women should be apprised of potential hazard to fetus and mother if therapy is administered during pregnancy"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Based on animal data, drug is not predicted to increase risk of major developmental abnormalities"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown whether therapy is excreted in human milk; in lactating rats, passage of enoxaparin or metabolites in milk is very limited; there is no information available on effect of enoxaparin or metabolites on breastfed child, or on milk production; developmental and health benefits of breastfeeding should be considered along with mother's clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition",
            "Lactation: Excretion in milk unknown; not recommended"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Epidural or spinal hematomas may occur in patients anticoagulated with low-molecular-weight heparin (LMWH) or heparinoids who receive neuraxial (epidural/spinal) anesthesia or spinal puncture",
                "These hematomas may result in long-term or permanent paralysis",
                "Patients should be frequently monitored for signs and symptoms of neurologic impairment (eg, tingling, numbness, muscular weakness)",
                "If neurologic compromise is noted, urgent treatment is necessary",
                "Physicians should consider the benefits versus risk before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis"
            ],
            "specific": [
                {
                    "type": "Factors increasing risk of epidural or spinal hematomas",
                    "description": [
                        "Indwelling epidural catheters",
                        "Concomitant use of other drugs that affect hemostasis (eg, NSAIDs, platelet inhibitors, other anticoagulants)",
                        "History of traumatic or repeated epidural or spinal punctures",
                        "History of spinal deformity or spinal surgery"
                    ]
                },
                {
                    "type": "Appropriate timing of enoxaparin dosing in relation to catheter placement or removal",
                    "description": [
                        "Optimal timing between the administration of enoxaparin and neuraxial procedures is not known",
                        "Placement or removal of a spinal catheter should be delayed for at least 12 hr after administration of prophylactic doses (eg, doses used for DVT prevention)",
                        "Longer delays (24 hr) are appropriate to consider for patients receiving higher therapeutic doses (eg, enoxaparin 1 mg/kg BID or 1.5 mg/kg qDay)",
                        "A post procedure dose of enoxaparin should usually be given no sooner than 4 hr after catheter removal",
                        "In all cases, a benefit-risk assessment should consider both the risk for thrombosis and the risk for bleeding in the context of the procedure and patient risk factors"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Active major bleeding, thrombocytopenia with antiplatelet antibody in presence of enoxaparin or heparin",
                "History of heparin-induced thrombocytopenia (HIT) within past 100 days or in presence of circulating antibodies",
                "Hypersensitivity to enoxaparin, heparin, pork products, benzyl alcohol (multiple dose formulations only) or other ingredients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Epidural or spinal hemorrhage and subsequent hematomas reported with the use of enoxaparin and epidural or spinal anesthesia/analgesia or spinal puncture procedures, resulting in long-term or permanent paralysis (see Black Box Warnings)",
                "Use with caution in patients with a bleeding diathesis, uncontrolled arterial hypertension or a history of recent gastrointestinal ulceration, diabetic retinopathy, renal dysfunction and hemorrhage",
                "Bleeding may occur; monitor patients with risk factors including congenital or acquired bleeding disorders, bacterial endocarditis, severe uncontrolled hypertension, hemorrhagic stroke, used shortly after brain, spinal, or ophthalmic surgery in patients treated concomitantly with platelet inhibitors or history of heparin induced thrombocytopenia, severe liver disease, diabetic retinopathy, patients undergoing invasive procedures, active ulcerative or angiodysplastic diseases, recent GI bleeding or ulceration",
                "To minimize risk of bleeding following PCI, achieve hemostasis, at puncture site after PCI; sheath can be removed immediately if closure device used; if manual compression used remove sheath 6 hr after last IV/SC dose of enoxaparin; additional doses not recommended until 6-8 hr after sheath removal; observe for signs of bleeding/hematoma formation",
                "Multidose formulation contains benzyl alcohol preservative, linked to fatal \"gasping syndrome\" in premature neonates",
                "Monitor for hyperkalemia (possibly from aldosterone suppression); mainly a concern among patients with risk factors including renal dysfunction, concomitant use of potassium sparing diuretics or potassium supplements",
                "Enoxaparin-induced thrombocytopenia and thrombosis reported; use extreme caution or avoid in patients with history heparin induced thrombocytopenia (HIT), especially if administered within 100 days of HIT episode; monitor platelet count closely; discontinue therapy and consider alternate treatment if platelets are <100,000/mm³ and/or thrombosis develops",
                "Not for long-term thrombocytopenia in patients with prosthetic heart valves",
                "Heparin-induced thrombocytopenia with thrombosis (HITTS) may lead to organ infarction, limb ischemia, or death; monitor thrombocytopenia of any degree closely",
                "Not for IM administration",
                "Use caution in patients with renal impairment",
                "Safety and efficacy not established in obese patients (>30 kg/m²)",
                "Risk of bleeding may increase in women <45 kg and men <57 kg",
                "Not for use interchangeably (unit for unit) with heparin or any LMWHs",
                "Use of therapy for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves may result in valve thrombosis"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "defibrotide",
            "description": {
                "common": "defibrotide increases effects of enoxaparin by pharmacodynamic synergism. Contraindicated. Coadministration of defibrotide is contraindicated with antithrombotic/fibrinolytic drugs. This does not include use for routine maintenance or reopening of central venous lines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone, enoxaparin. Other (see comment). Contraindicated. \nComment: Mifepristone may lead to excessive post abortion bleeding in pts. on anticoagulant therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "prothrombin complex concentrate, human",
            "description": {
                "common": "enoxaparin, prothrombin complex concentrate, human. pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abciximab",
            "description": {
                "common": "enoxaparin, abciximab.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital decreases effects of enoxaparin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anagrelide",
            "description": {
                "common": "enoxaparin, anagrelide.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "antithrombin alfa and enoxaparin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "antithrombin III and enoxaparin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apixaban",
            "description": {
                "common": "enoxaparin and apixaban both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "argatroban",
            "description": {
                "common": "argatroban and enoxaparin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "azithromycin",
            "description": {
                "common": "azithromycin increases effects of enoxaparin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bazedoxifene/conjugated estrogens",
            "description": {
                "common": "bazedoxifene/conjugated estrogens decreases effects of enoxaparin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bemiparin",
            "description": {
                "common": "bemiparin and enoxaparin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "bivalirudin and enoxaparin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital decreases effects of enoxaparin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital decreases effects of enoxaparin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "capecitabine",
            "description": {
                "common": "capecitabine increases effects of enoxaparin by unspecified interaction mechanism. Avoid or Use Alternate Drug. An additive risk of bleeding with enoxaparin may be seen in thrombocytopenic patients receiving antineoplastic agents like capecitabine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "caplacizumab",
            "description": {
                "common": "caplacizumab, enoxaparin.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefamandole",
            "description": {
                "common": "cefamandole increases effects of enoxaparin by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefazolin",
            "description": {
                "common": "cefazolin increases effects of enoxaparin by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefdinir",
            "description": {
                "common": "cefdinir increases effects of enoxaparin by anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefditoren",
            "description": {
                "common": "cefditoren will increase the level or effect of enoxaparin by  anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefotetan",
            "description": {
                "common": "cefotetan increases effects of enoxaparin by anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefoxitin",
            "description": {
                "common": "cefoxitin will increase the level or effect of enoxaparin by  anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefpodoxime",
            "description": {
                "common": "cefpodoxime will increase the level or effect of enoxaparin by  anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ceftriaxone",
            "description": {
                "common": "ceftriaxone increases effects of enoxaparin by anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefuroxime",
            "description": {
                "common": "cefuroxime will increase the level or effect of enoxaparin by  anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cilostazol",
            "description": {
                "common": "enoxaparin, cilostazol.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin increases effects of enoxaparin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "conjugated estrogens decreases effects of enoxaparin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dabigatran",
            "description": {
                "common": "dabigatran and enoxaparin both increase  anticoagulation. Avoid or Use Alternate Drug. Caution is advised, both drugs have the potential to cause bleeding. Concomitant use may increase risk of bleeding."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dalteparin",
            "description": {
                "common": "dalteparin and enoxaparin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dipyridamole",
            "description": {
                "common": "enoxaparin, dipyridamole.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "edoxaban",
            "description": {
                "common": "edoxaban, enoxaparin.\nEither increases toxicity of the other by anticoagulation. Avoid or Use Alternate Drug. Both drugs have the potential to cause bleeding, monitor closely. Promptly evaluate any signs or symptoms of blood loss. Long-term concomitant treatment with edoxaban and other anticoagulants is not recommended. Short-term coadministration may be needed for patients transitioning to or from edoxaban."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eptifibatide",
            "description": {
                "common": "enoxaparin, eptifibatide.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base increases effects of enoxaparin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate increases effects of enoxaparin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate increases effects of enoxaparin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate increases effects of enoxaparin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estradiol",
            "description": {
                "common": "estradiol decreases effects of enoxaparin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estrogens conjugated synthetic",
            "description": {
                "common": "estrogens conjugated synthetic decreases effects of enoxaparin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estropipate",
            "description": {
                "common": "estropipate decreases effects of enoxaparin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "ethinylestradiol decreases effects of enoxaparin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Factor X, human",
            "description": {
                "common": "enoxaparin will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "enoxaparin and fondaparinux both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "heparin",
            "description": {
                "common": "enoxaparin and heparin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel intrauterine",
            "description": {
                "common": "levonorgestrel intrauterine, enoxaparin.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel oral",
            "description": {
                "common": "levonorgestrel oral, enoxaparin.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "liothyronine",
            "description": {
                "common": "liothyronine increases effects of enoxaparin by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mestranol",
            "description": {
                "common": "mestranol decreases effects of enoxaparin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital decreases effects of enoxaparin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenindione",
            "description": {
                "common": "enoxaparin and phenindione both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital decreases effects of enoxaparin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "piperacillin",
            "description": {
                "common": "piperacillin increases effects of enoxaparin by anticoagulation. Avoid or Use Alternate Drug. Piperacillin can inhibit platelet aggregation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone decreases effects of enoxaparin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "protamine",
            "description": {
                "common": "enoxaparin and protamine both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinine",
            "description": {
                "common": "quinine increases effects of enoxaparin by unknown mechanism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "roxithromycin",
            "description": {
                "common": "roxithromycin increases effects of enoxaparin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital decreases effects of enoxaparin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "sulfadiazine increases effects of enoxaparin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "sulfamethoxazole increases effects of enoxaparin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sulfisoxazole",
            "description": {
                "common": "sulfisoxazole increases effects of enoxaparin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thyroid desiccated",
            "description": {
                "common": "thyroid desiccated increases effects of enoxaparin by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tibolone",
            "description": {
                "common": "tibolone increases effects of enoxaparin by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ticlopidine",
            "description": {
                "common": "enoxaparin, ticlopidine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tirofiban",
            "description": {
                "common": "enoxaparin, tirofiban.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "enoxaparin, zanubrutinib.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib increases effects of enoxaparin by anticoagulation. Use Caution/Monitor. Coadministration of acalabrutinib with antiplatelets or anticoagulants may further increase risk of hemorrhage. Monitor for signs of bleeding and consider the benefit-risk of withholding acalabrutinib for 3-7 days presurgery and postsurgery depending upon the type of surgery and the risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aceclofenac",
            "description": {
                "common": "enoxaparin and aceclofenac both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acemetacin",
            "description": {
                "common": "enoxaparin and acemetacin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "agrimony",
            "description": {
                "common": "enoxaparin and agrimony both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfalfa",
            "description": {
                "common": "enoxaparin and alfalfa both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alteplase",
            "description": {
                "common": "enoxaparin and alteplase both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "American ginseng",
            "description": {
                "common": "enoxaparin and American ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiloride",
            "description": {
                "common": "amiloride, enoxaparin.\nEither increases toxicity of the other by serum potassium. Use Caution/Monitor. Both drugs may increase serum potassium levels."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anamu",
            "description": {
                "common": "enoxaparin and anamu both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "enoxaparin and aspirin both increase  anticoagulation. Use Caution/Monitor. Additive effects are intended when both drugs are prescribed as indicated for unstable angina, non-Q-wave MI, and STEMI"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "enoxaparin and aspirin rectal both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "aspirin/citric acid/sodium bicarbonate, enoxaparin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azapropazone",
            "description": {
                "common": "azapropazone increases effects of enoxaparin by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azathioprine",
            "description": {
                "common": "azathioprine decreases effects of enoxaparin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azficel-T",
            "description": {
                "common": "azficel-T, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Coadministration with anticoagulants or antiplatelets may increase bruising or bleeding at biopsy and/or injection sites; concomitant use not recommended. Decisions regarding continued use or cessation of anticoagulants or antiplatelets should be made by a physician."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azilsartan",
            "description": {
                "common": "enoxaparin increases toxicity of azilsartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "enoxaparin increases toxicity of benazepril by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betrixaban",
            "description": {
                "common": "enoxaparin, betrixaban.\nEither increases levels of the other by anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "budesonide",
            "description": {
                "common": "budesonide, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "candesartan",
            "description": {
                "common": "enoxaparin increases toxicity of candesartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "enoxaparin increases toxicity of captopril by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine decreases levels of enoxaparin by increasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "enoxaparin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chitosan",
            "description": {
                "common": "chitosan increases effects of enoxaparin by Other (see comment). Use Caution/Monitor. \nComment: Chitosan can decrease GI absorption of vitamin K, enhancing anticoagulant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "enoxaparin and choline magnesium trisalicylate both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cinnamon",
            "description": {
                "common": "enoxaparin and cinnamon both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram increases effects of enoxaparin by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "enoxaparin, clopidogrel.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Enhanced risk of hemorrhage; additive effects are intended when both drugs are prescribed as indicated for ACS."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "collagenase clostridium histolyticum",
            "description": {
                "common": "enoxaparin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens, vaginal",
            "description": {
                "common": "conjugated estrogens, vaginal decreases effects of enoxaparin by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cordyceps",
            "description": {
                "common": "enoxaparin and cordyceps both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cornsilk",
            "description": {
                "common": "cornsilk decreases effects of enoxaparin by pharmacodynamic antagonism. Use Caution/Monitor. Cornsilk contains vitamin K; consume a consistent amount daily."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide increases effects of enoxaparin by unknown mechanism. Use Caution/Monitor. Due to potential thrombocytopenic effects of cyclophosphamide, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "danshen",
            "description": {
                "common": "enoxaparin and danshen both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferasirox",
            "description": {
                "common": "deferasirox, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Gastric ulceration and GI bleeding have been reported in patients taking deferasirox, use caution when coadministering with other drugs known to increase the risk of peptic ulcers or gastric hemorrhage including anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "devil's claw",
            "description": {
                "common": "enoxaparin and devil's claw both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "enoxaparin and diclofenac both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "enoxaparin and diflunisal both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dong quai",
            "description": {
                "common": "enoxaparin and dong quai both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enalapril",
            "description": {
                "common": "enoxaparin increases toxicity of enalapril by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epoprostenol",
            "description": {
                "common": "enoxaparin and epoprostenol both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eprosartan",
            "description": {
                "common": "enoxaparin increases toxicity of eprosartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethanol",
            "description": {
                "common": "ethanol increases effects of enoxaparin by unknown mechanism. Use Caution/Monitor. Acute EtOH intoxication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethotoin",
            "description": {
                "common": "enoxaparin increases levels of ethotoin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "enoxaparin and etodolac both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenbufen",
            "description": {
                "common": "enoxaparin and fenbufen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fennel",
            "description": {
                "common": "enoxaparin and fennel both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "enoxaparin and fenoprofen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "feverfew",
            "description": {
                "common": "enoxaparin and feverfew both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fish oil",
            "description": {
                "common": "fish oil, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking fish oil and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fish oil triglycerides",
            "description": {
                "common": "fish oil triglycerides will increase the level or effect of enoxaparin by  anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluorouracil",
            "description": {
                "common": "fluorouracil increases effects of enoxaparin by unspecified interaction mechanism. Use Caution/Monitor. Due to the thrombocytopenic effects of fluorouracil, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "enoxaparin and flurbiprofen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "forskolin",
            "description": {
                "common": "enoxaparin and forskolin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosinopril",
            "description": {
                "common": "enoxaparin increases toxicity of fosinopril by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "enoxaparin increases levels of fosphenytoin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "garlic",
            "description": {
                "common": "enoxaparin and garlic both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemcitabine",
            "description": {
                "common": "gemcitabine increases effects of enoxaparin by unspecified interaction mechanism. Use Caution/Monitor. Due to the thrombocytopenic effects of gemcitabine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ginger",
            "description": {
                "common": "enoxaparin and ginger both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ginkgo biloba",
            "description": {
                "common": "enoxaparin and ginkgo biloba both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glucagon intranasal",
            "description": {
                "common": "glucagon intranasal increases effects of enoxaparin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "green tea",
            "description": {
                "common": "green tea, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of bleeding, caution is advised."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hemin",
            "description": {
                "common": "enoxaparin, hemin.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Hemin degradation product (ie, hematin) may produce coagulopathy (eg, thrombocytopenia, platelet degranulation) and cause mild anticoagulant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "horse chestnut seed",
            "description": {
                "common": "enoxaparin and horse chestnut seed both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "ibrutinib will increase the level or effect of enoxaparin by  anticoagulation. Use Caution/Monitor. Ibrutinib may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and monitor for signs of bleeding. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "enoxaparin and ibuprofen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "enoxaparin and ibuprofen IV both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "icosapent",
            "description": {
                "common": "icosapent, enoxaparin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib, enoxaparin.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents; patients requiring anticoagulation while on imatinib should receive LMWH or unfractionated heparin instead of warfarin because of multiple interaction mechanisms of imatinib with warfarin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "enoxaparin and indomethacin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iodine (radioactive)",
            "description": {
                "common": "iodine (radioactive) decreases effects of enoxaparin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irbesartan",
            "description": {
                "common": "enoxaparin increases toxicity of irbesartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "enoxaparin and ketoprofen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "enoxaparin and ketorolac both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "enoxaparin and ketorolac intranasal both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisinopril",
            "description": {
                "common": "enoxaparin increases toxicity of lisinopril by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "lofepramine increases levels of enoxaparin by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lornoxicam",
            "description": {
                "common": "enoxaparin and lornoxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "enoxaparin increases toxicity of losartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "enoxaparin and meclofenamate both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "enoxaparin and mefenamic acid both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "melatonin",
            "description": {
                "common": "melatonin increases effects of enoxaparin by anticoagulation. Use Caution/Monitor. Melatonin may decrease prothrombin time."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meloxicam",
            "description": {
                "common": "enoxaparin and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methimazole",
            "description": {
                "common": "methimazole decreases effects of enoxaparin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mistletoe",
            "description": {
                "common": "enoxaparin increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moexipril",
            "description": {
                "common": "enoxaparin increases toxicity of moexipril by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "enoxaparin and nabumetone both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "enoxaparin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nettle",
            "description": {
                "common": "enoxaparin increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nintedanib",
            "description": {
                "common": "nintedanib increases effects of enoxaparin by anticoagulation. Use Caution/Monitor. Nintedanib is a VEGFR inhibitor, and may increase the risk of bleeding; monitor patients on full anticoagulation therapy; monitor closely for bleeding and adjust therapy as needed ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olmesartan",
            "description": {
                "common": "enoxaparin increases toxicity of olmesartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omega 3 carboxylic acids",
            "description": {
                "common": "omega 3 carboxylic acids, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3 acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omega 3 fatty acids",
            "description": {
                "common": "omega 3 fatty acids, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "enoxaparin and oxaprozin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "panax ginseng",
            "description": {
                "common": "enoxaparin and panax ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "parecoxib",
            "description": {
                "common": "enoxaparin and parecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pau d'arco",
            "description": {
                "common": "enoxaparin and pau d'arco both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegaspargase",
            "description": {
                "common": "pegaspargase increases effects of enoxaparin by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of bleeding events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perindopril",
            "description": {
                "common": "enoxaparin increases toxicity of perindopril by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "enoxaparin increases levels of phenytoin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phytoestrogens",
            "description": {
                "common": "enoxaparin and phytoestrogens both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "enoxaparin and piroxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "porfimer",
            "description": {
                "common": "enoxaparin decreases effects of porfimer by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prasugrel",
            "description": {
                "common": "enoxaparin, prasugrel.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propafenone",
            "description": {
                "common": "propafenone increases effects of enoxaparin by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propylthiouracil",
            "description": {
                "common": "propylthiouracil decreases effects of enoxaparin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinapril",
            "description": {
                "common": "enoxaparin increases toxicity of quinapril by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ramipril",
            "description": {
                "common": "enoxaparin increases toxicity of ramipril by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "reishi",
            "description": {
                "common": "enoxaparin and reishi both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "reteplase",
            "description": {
                "common": "enoxaparin and reteplase both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin decreases levels of enoxaparin by increasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "rivaroxaban, enoxaparin.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Avoid concurrent use of rivaroxaban with other anticoagulants due to increased bleeding risk other than during therapeutic transition periods where patients should be observed closely. Monitor for signs/symptoms of blood loss."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "enoxaparin increases toxicity of sacubitril/valsartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "enoxaparin and salicylates (non-asa) both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "enoxaparin and salsalate both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saw palmetto",
            "description": {
                "common": "saw palmetto increases toxicity of enoxaparin by unspecified interaction mechanism. Use Caution/Monitor. May increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "Siberian ginseng",
            "description": {
                "common": "enoxaparin and Siberian ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "spironolactone",
            "description": {
                "common": "spironolactone, enoxaparin.\nEither increases toxicity of the other by serum potassium. Use Caution/Monitor. Both drugs may increase serum potassium levels."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "enoxaparin and sulfasalazine both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "enoxaparin and sulindac both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telmisartan",
            "description": {
                "common": "enoxaparin increases toxicity of telmisartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenecteplase",
            "description": {
                "common": "enoxaparin and tenecteplase both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticagrelor",
            "description": {
                "common": "ticagrelor, enoxaparin.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Increased risk of bleeding during concomitant use of medications that increase potential for bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir increases effects of enoxaparin by pharmacodynamic synergism. Use Caution/Monitor. Tipranavir has mild antiplatelet activity that may incr bleeding risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolfenamic acid",
            "description": {
                "common": "enoxaparin and tolfenamic acid both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolmetin",
            "description": {
                "common": "enoxaparin and tolmetin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trandolapril",
            "description": {
                "common": "enoxaparin increases toxicity of trandolapril by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamterene",
            "description": {
                "common": "triamterene, enoxaparin.\nEither increases toxicity of the other by serum potassium. Use Caution/Monitor. Both drugs may increase serum potassium levels."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triclofos",
            "description": {
                "common": "triclofos increases effects of enoxaparin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valsartan",
            "description": {
                "common": "enoxaparin increases toxicity of valsartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vorapaxar",
            "description": {
                "common": "enoxaparin, vorapaxar.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Coadministration of anticoagulants, antiplatelets, or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "vortioxetine and enoxaparin both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen",
            "description": {
                "common": "acetaminophen increases effects of enoxaparin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen IV",
            "description": {
                "common": "acetaminophen IV increases effects of enoxaparin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen rectal",
            "description": {
                "common": "acetaminophen rectal increases effects of enoxaparin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alprostadil intracavernous/urethral",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of enoxaparin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ceftaroline",
            "description": {
                "common": "ceftaroline increases effects of enoxaparin by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorella",
            "description": {
                "common": "chlorella decreases effects of enoxaparin by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical, due to vitamin K content."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "demeclocycline increases effects of enoxaparin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexmethylphenidate",
            "description": {
                "common": "dexmethylphenidate increases effects of enoxaparin by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxycycline",
            "description": {
                "common": "doxycycline increases effects of enoxaparin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glyburide",
            "description": {
                "common": "glyburide increases effects of enoxaparin by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mineral oil",
            "description": {
                "common": "mineral oil decreases levels of enoxaparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "minocycline",
            "description": {
                "common": "minocycline increases effects of enoxaparin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxytetracycline",
            "description": {
                "common": "oxytetracycline increases effects of enoxaparin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine increases effects of enoxaparin by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "serdexmethylphenidate/dexmethylphenidate",
            "description": {
                "common": "serdexmethylphenidate/dexmethylphenidate increases effects of enoxaparin by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tetracycline",
            "description": {
                "common": "tetracycline increases effects of enoxaparin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "verteporfin",
            "description": {
                "common": "enoxaparin decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin E",
            "description": {
                "common": "vitamin E, enoxaparin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Hemorrhage",
            "percent": "1-4"
        },
        {
            "name": "Elevation of serum aminotransferases",
            "percent": "6"
        },
        {
            "name": "Fever",
            "percent": "5-8"
        },
        {
            "name": "Local site reactions",
            "percent": "2-5"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "3"
        },
        {
            "name": "Nausea",
            "percent": "3"
        },
        {
            "name": "Anemia",
            "percent": "2"
        },
        {
            "name": "Ecchymosis",
            "percent": "3"
        },
        {
            "name": "Atrial fibrillation",
            "percent": null
        },
        {
            "name": "Heart failure",
            "percent": null
        },
        {
            "name": "Pulmonary edema",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        },
        {
            "name": "Reports of epidural or spinal hematoma formation when coadministered with spinal",
            "percent": null
        },
        {
            "name": "epidural anesthesia or spinal puncture",
            "percent": null
        },
        {
            "name": "Local reactions at the injection site",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "nodules",
            "percent": null
        },
        {
            "name": "inflammation",
            "percent": null
        },
        {
            "name": "oozing",
            "percent": null
        },
        {
            "name": "systemic allergic reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "anaphylactic",
            "percent": null
        },
        {
            "name": "anaphylactoid reactions including shock",
            "percent": null
        },
        {
            "name": "vesiculobullous rash",
            "percent": null
        },
        {
            "name": "rare cases of hypersensitivity cutaneous vasculitis",
            "percent": null
        },
        {
            "name": "purpura",
            "percent": null
        },
        {
            "name": "skin necrosis",
            "percent": null
        },
        {
            "name": "occurring at either the injection site or distant from the injection site",
            "percent": null
        },
        {
            "name": "thrombocytosis",
            "percent": null
        },
        {
            "name": "and thrombocytopenia with thrombosis",
            "percent": null
        },
        {
            "name": "Hyperkalemia",
            "percent": null
        },
        {
            "name": "Cases of headache",
            "percent": null
        },
        {
            "name": "hemorrhagic anemia",
            "percent": null
        },
        {
            "name": "eosinophilia",
            "percent": null
        },
        {
            "name": "alopecia",
            "percent": null
        },
        {
            "name": "hepatocellular and cholestatic liver injury reported",
            "percent": null
        },
        {
            "name": "Osteoporosis following long",
            "percent": null
        },
        {
            "name": "term therapy",
            "percent": null
        }
    ]
}